Superworth

Krystal Biotech price to free cash flow KRYS

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Nov 2, 2026
34.0×
Peer median
22.5×

Krystal Biotech's price to free cash flow is 34.0× as of Nov 2, 2026.

The median for 10 biotech stocks of a similar size is 22.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far34.0×34.0×49.9×
202544.2×21.6×79.1×
202478.9×78.9×98.9×

Against its peers

Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.

CompanyPrice to free cash flow
KRYSKrystal Biotech34.0×
RGENRepligen87.2×
TECHBIO-TECHNE43.3×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
ALNYAlnylam Pharmaceuticals26.7×
INCYIncyte12.7×
UTHRUnited Therapeutics23.7×
ADMAAdma Biologics21.3×
VCELVericel33.6×
Peer median22.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Krystal Biotech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.